Omeros (NASDAQ:OMER) Earns “Neutral” Rating from Cantor Fitzgerald

Omeros (NASDAQ:OMER)‘s stock had its “neutral” rating restated by equities researchers at Cantor Fitzgerald in a research report issued to clients and investors on Thursday,Benzinga reports.

Several other equities analysts have also recently issued reports on the company. Rodman & Renshaw started coverage on Omeros in a research note on Thursday. They issued a “buy” rating and a $9.00 price objective for the company. Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a research note on Thursday. Finally, StockNews.com cut shares of Omeros from a “hold” rating to a “sell” rating in a research report on Tuesday.

Omeros Stock Performance

Shares of OMER traded up $1.19 during midday trading on Thursday, hitting $5.38. 483,938 shares of the stock were exchanged, compared to its average volume of 396,456. The firm has a market cap of $311.77 million, a P/E ratio of -2.23 and a beta of 1.47. Omeros has a 52-week low of $1.38 and a 52-week high of $5.68. The stock has a fifty day simple moving average of $4.02 and a 200 day simple moving average of $4.05.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets raised its stake in shares of Omeros by 130.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 7,016 shares during the last quarter. SPC Financial Inc. acquired a new position in Omeros during the third quarter worth about $77,000. SG Americas Securities LLC purchased a new stake in shares of Omeros in the third quarter valued at about $80,000. Oppenheimer & Co. Inc. acquired a new stake in shares of Omeros in the first quarter valued at approximately $85,000. Finally, Comerica Bank increased its stake in shares of Omeros by 20.0% during the 1st quarter. Comerica Bank now owns 30,000 shares of the biopharmaceutical company’s stock worth $104,000 after purchasing an additional 5,000 shares in the last quarter. 48.79% of the stock is owned by hedge funds and other institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.